PARS/PARP Inhibitors (Bayer)

N/A

Report date: 2025/02/01 20:00:06

NME

Base Information

Drug NamePARS/PARP Inhibitors (Bayer)

Drug Alias NamePARP Inhibitors (Bayer)Poly-(ADP-Ribose) Polymerase Inhibitors (Bayer)Poly-(ADP-Ribose) Synthetase Inhibitors (Bayer)PARS Inhibitors (Bayer)Poly-(ADP-Ribose) Synthetase/Polymerase Inhibitors (Bayer)

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPoly (ADP-Ribose) polymerase inhibitors

TargetsPoly (ADP-Ribose) polymerase

Therapy Area/IndicationsIschemiaNeurotoxicity Syndromes

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBayer AG

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBayer AG

Active IndicationsN/A

Inactive IndicationsIschemiaNeurotoxicity Syndromes

Other Information

ATC CodeN/A